3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
5
Sarcoma, Endometrial Stromal
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Advanced Breast Cancer
1
Adenosarcoma of the uterus
1
Interventions
Magnetic Resonance Spectroscopy
8
Specimen Handling
7
Biopsy
6
X-Rays
5
Phantoms, Imaging
5
Temozolomide
4
Nuclear Medicine Department, Hospital
4
Nivolumab
4
Carboplatin
4
selpercatinib
3
larotrectinib
3
Topotecan
3
Etoposide
3
Cyclophosphamide
3
Cisplatin
3
Automobiles
3
tazemetostat
2
pembrolizumab
2
erdafitinib
2
entrectinib
2
ensartinib
2
cabozantinib
2
Vincristine
2
Surveys and Questionnaires
2
Radiotherapy
2
Radiosurgery
2
Radiation
2
Positron-Emission Tomography
2
Paclitaxel
2
ONC206
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
RAD1901
×
1 year
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled